What is Fahr's syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025 • View editorial policy

From the Research

Fahr's syndrome is a rare neurological disorder that requires early diagnosis and treatment to slow progression and improve quality of life, with a focus on addressing underlying calcium metabolism disorders and symptomatic relief. The condition is characterized by abnormal calcium deposits in the brain's basal ganglia and cerebral cortex, leading to a combination of movement disorders, cognitive impairment, speech difficulties, and psychiatric symptoms 1. Diagnosis involves brain imaging, such as CT scans, which are more sensitive than MRI for detecting calcifications, and laboratory tests to check calcium, phosphate, and parathyroid hormone levels 2, 3.

Key Features of Fahr's Syndrome

  • Abnormal calcium deposits in the brain's basal ganglia and cerebral cortex
  • Movement disorders, such as parkinsonism, chorea, or dystonia
  • Cognitive impairment, speech difficulties, and psychiatric symptoms
  • Disruptions in calcium and phosphate metabolism, particularly hypoparathyroidism

Treatment and Management

  • Addressing underlying calcium metabolism disorders, particularly normalizing calcium levels if hypoparathyroidism is present, with calcium supplementation (1-2g daily) and active vitamin D (calcitriol 0.25-1 mcg daily) 2
  • Symptomatic treatment, including medications for movement disorders, antipsychotics for psychiatric symptoms, and anticonvulsants if seizures occur
  • Early diagnosis and treatment may help slow progression and improve quality of life, with a focus on individualized treatment plans and regular monitoring 1

Recent Evidence and Recommendations

  • A recent case report and literature review highlights the importance of early diagnosis and treatment of Fahr's syndrome, with a focus on addressing underlying calcium metabolism disorders and symptomatic relief 1
  • The use of combination therapy, including aripiprazole, trihexyphenidyl, and botulinum toxin, may be effective in managing segmental craniocervical dystonia, a condition related to Fahr's syndrome 4

References

Research

Fahr's syndrome: literature review of current evidence.

Orphanet journal of rare diseases, 2013

Research

Fahr's syndrome: diagnosis issues in patients with unknown family history of disease.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2009

Research

Combination therapy for segmental craniocervical dystonia (Meige syndrome) with aripiprazole, trihexyphenidyl, and botulinum toxin: three cases reports.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.